Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > Q&A – Pharmacovigilance Legislation

CMDh_257_2012_Rev22_2020_10_clean_-_QA_on_PhV

Philippe Calandra 13 November 2020 All news
  • ← ICH-Endorsed Guide for MedDRA Users
  • EMA publishes safety monitoring plan and guidance on risk management planning for COVID-19 vaccines →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • European regulation on clinical trials for medicinal products: The end of the transition period
  • The ANSM publishes its haemovigilance report for 2023
  • User’s booklet – ANSM
Copyright © 2018 - Pharmya - Legal terms - Quality Policy